A leading integrated biopharmaceutical company and preferred CDMO, Bioplus Lifesciences brings expertise in novel drug development and microbial fermentation, operating an oral dosage form facility inspected and approved by EU-GMP, MHRA, Health Canada and TGA, capable of manufacturing effervescent tablets. The company is focused on addressing unmet medical needs with an innovative portfolio, including clinical-stage programs for MASH and pulmonary TB, and its subsidiary Theialife develops a novel portfolio of ophthalmology assets, with additional certifications including ISO, BRCGS, NSF, TUV, WHO GMP and GRMA.
Aucun commentaire disponible.
Laissez votre note & commentaire